Baseline characteristics of the UK, Australian and Dutch cohorts
| UK Cohort 1 n=221 | Australian Cohort n=253 | Dutch Cohort n=315 | UK Cohort 2 n=83 | |
|---|---|---|---|---|
| Age, median (IQR) | 74 (67–80) | 69 (63–78) | 60 (53–66) | 71 (61–76) |
| % Men | 62.0 | 65.6 | 38.1 | 60.2 |
| % Right sided | 57.0 | 61.0 | 57.3 | 63.9 |
| Mode of diagnosis, n (%) | ||||
| Pleural cytology, flow cytometry or pleural biopsy | 150 (68) | 205 (81) | 213 (68) | 54 (65) |
| Otherwise unexplained effusion with confirmed malignancy elsewhere | 54 (24) | 48 (19) | 102 (32) | 25 (30) |
| Radiological evidence of malignancy with no histo-cytological proof | 17 (8) | 0 | 0 | 4 (5) |
| Cell type, n (%) | ||||
| Mesothelioma | 58 (26) | 96 (38) | 16 (5) | 17 (20) |
| Lung cancer | 66 (30) | 72 (28) | 77 (24) | 33 (40) |
| Gynaecological cancer | 20 (9) | 17 (7) | 22 (7) | 4 (5) |
| Breast cancer | 26 (12) | 25 (10) | 89 (28) | 11 (13) |
| Gastrointestinal cancer | 10 (5) | 8 (3) | 43 (14) | 3 (4) |
| Haematological malignancy | 13 (6) | 15 (6) | 7 (2) | 7 (8) |
| Other | 28 (13) | 20 (8) | 61 (19) | 8 (10) |
| Overall median survival, days (95% CI) | 168 (108 to 228) | 205 (167 to 238) | 84 (72 to 115) | 193 (97 to 332) |